0001538217
false
--12-31
Q3
0001538217
2022-01-01
2022-09-30
0001538217
2023-10-20
0001538217
2022-09-30
0001538217
2021-12-31
0001538217
us-gaap:CommonClassAMember
2022-09-30
0001538217
us-gaap:CommonClassAMember
2021-12-31
0001538217
us-gaap:CommonClassBMember
2022-09-30
0001538217
us-gaap:CommonClassBMember
2021-12-31
0001538217
us-gaap:SeriesAPreferredStockMember
2022-09-30
0001538217
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001538217
2022-07-01
2022-09-30
0001538217
2021-07-01
2021-09-30
0001538217
2021-01-01
2021-09-30
0001538217
us-gaap:PreferredStockMember
2021-12-31
0001538217
us-gaap:CommonStockMember
2021-12-31
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001538217
us-gaap:RetainedEarningsMember
2021-12-31
0001538217
us-gaap:NoncontrollingInterestMember
2021-12-31
0001538217
us-gaap:PreferredStockMember
2022-03-31
0001538217
us-gaap:CommonStockMember
2022-03-31
0001538217
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001538217
us-gaap:RetainedEarningsMember
2022-03-31
0001538217
us-gaap:NoncontrollingInterestMember
2022-03-31
0001538217
2022-03-31
0001538217
us-gaap:PreferredStockMember
2022-06-30
0001538217
us-gaap:CommonStockMember
2022-06-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001538217
us-gaap:RetainedEarningsMember
2022-06-30
0001538217
us-gaap:NoncontrollingInterestMember
2022-06-30
0001538217
2022-06-30
0001538217
us-gaap:PreferredStockMember
2020-12-31
0001538217
us-gaap:CommonStockMember
2020-12-31
0001538217
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001538217
us-gaap:RetainedEarningsMember
2020-12-31
0001538217
us-gaap:NoncontrollingInterestMember
2020-12-31
0001538217
2020-12-31
0001538217
us-gaap:PreferredStockMember
2021-03-31
0001538217
us-gaap:CommonStockMember
2021-03-31
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001538217
us-gaap:RetainedEarningsMember
2021-03-31
0001538217
us-gaap:NoncontrollingInterestMember
2021-03-31
0001538217
2021-03-31
0001538217
us-gaap:PreferredStockMember
2021-06-30
0001538217
us-gaap:CommonStockMember
2021-06-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-06-30
0001538217
us-gaap:RetainedEarningsMember
2021-06-30
0001538217
us-gaap:NoncontrollingInterestMember
2021-06-30
0001538217
2021-06-30
0001538217
us-gaap:PreferredStockMember
2022-01-01
2022-03-31
0001538217
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001538217
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001538217
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001538217
us-gaap:NoncontrollingInterestMember
2022-01-01
2022-03-31
0001538217
2022-01-01
2022-03-31
0001538217
us-gaap:PreferredStockMember
2022-04-01
2022-06-30
0001538217
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001538217
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001538217
us-gaap:NoncontrollingInterestMember
2022-04-01
2022-06-30
0001538217
2022-04-01
2022-06-30
0001538217
us-gaap:PreferredStockMember
2022-07-01
2022-09-30
0001538217
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001538217
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001538217
us-gaap:NoncontrollingInterestMember
2022-07-01
2022-09-30
0001538217
us-gaap:PreferredStockMember
2021-01-01
2021-03-31
0001538217
us-gaap:CommonStockMember
2021-01-01
2021-03-31
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-03-31
0001538217
us-gaap:RetainedEarningsMember
2021-01-01
2021-03-31
0001538217
us-gaap:NoncontrollingInterestMember
2021-01-01
2021-03-31
0001538217
2021-01-01
2021-03-31
0001538217
us-gaap:PreferredStockMember
2021-04-01
2021-06-30
0001538217
us-gaap:CommonStockMember
2021-04-01
2021-06-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2021-06-30
0001538217
us-gaap:RetainedEarningsMember
2021-04-01
2021-06-30
0001538217
us-gaap:NoncontrollingInterestMember
2021-04-01
2021-06-30
0001538217
2021-04-01
2021-06-30
0001538217
us-gaap:PreferredStockMember
2021-07-01
2021-09-30
0001538217
us-gaap:CommonStockMember
2021-07-01
2021-09-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-07-01
2021-09-30
0001538217
us-gaap:RetainedEarningsMember
2021-07-01
2021-09-30
0001538217
us-gaap:NoncontrollingInterestMember
2021-07-01
2021-09-30
0001538217
us-gaap:PreferredStockMember
2022-09-30
0001538217
us-gaap:CommonStockMember
2022-09-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001538217
us-gaap:RetainedEarningsMember
2022-09-30
0001538217
us-gaap:NoncontrollingInterestMember
2022-09-30
0001538217
us-gaap:PreferredStockMember
2021-09-30
0001538217
us-gaap:CommonStockMember
2021-09-30
0001538217
us-gaap:AdditionalPaidInCapitalMember
2021-09-30
0001538217
us-gaap:RetainedEarningsMember
2021-09-30
0001538217
us-gaap:NoncontrollingInterestMember
2021-09-30
0001538217
2021-09-30
0001538217
us-gaap:CustomerConcentrationRiskMember
us-gaap:AccountsReceivableMember
SRAX:OneCustomerMember
2021-01-01
2021-12-31
0001538217
SRAX:PotentiallyDilutedBasicInFutureMember
2022-01-01
2022-09-30
0001538217
SRAX:PotentiallyDilutedBasicInFutureMember
2022-07-01
2022-09-30
0001538217
SRAX:PotentiallyDilutedBasicInFutureMember
2021-01-01
2021-09-30
0001538217
SRAX:PotentiallyDilutedBasicInFutureMember
2021-07-01
2021-09-30
0001538217
SRAX:ForceProtectionVideoEquipmentCorpMember
SRAX:ExchangeAgreementMember
2021-02-04
0001538217
SRAX:ForceProtectionVideoEquipmentCorpMember
us-gaap:SeriesAPreferredStockMember
SRAX:ExchangeAgreementMember
2021-02-04
0001538217
SRAX:ForceProtectionVideoEquipmentCorpMember
SRAX:ExchangeAgreementMember
srt:MaximumMember
2021-02-04
0001538217
SRAX:ForceProtectionVideoEquipmentCorpMember
srt:MinimumMember
2021-02-04
0001538217
2021-12-28
2021-12-29
0001538217
SRAX:BritePoolIncMember
2021-12-28
2021-12-29
0001538217
SRAX:BritePoolIncMember
SRAX:SeriesDConvertiblePreferredStockMember
2021-12-28
2021-12-29
0001538217
SRAX:SeriesDConvertiblePreferredStockMember
2021-12-28
2021-12-29
0001538217
us-gaap:CommonStockMember
2021-12-28
2021-12-29
0001538217
2021-12-29
0001538217
2020-10-01
2020-10-31
0001538217
2020-10-31
0001538217
us-gaap:CustomerConcentrationRiskMember
SRAX:MarketableSecuritiesMember
SRAX:TopMarketableSecurityMember
2022-09-30
0001538217
us-gaap:CustomerConcentrationRiskMember
SRAX:MarketableSecuritiesMember
SRAX:TopMarketableSecurityMember
2022-01-01
2022-09-30
0001538217
us-gaap:CustomerConcentrationRiskMember
SRAX:MarketableSecuritiesMember
SRAX:TopFiveMarketableSecurityMember
2022-09-30
0001538217
us-gaap:CustomerConcentrationRiskMember
SRAX:MarketableSecuritiesMember
SRAX:TopFiveMarketableSecurityMember
2022-01-01
2022-09-30
0001538217
us-gaap:CustomerConcentrationRiskMember
SRAX:MarketableSecuritiesMember
SRAX:TopTenMarketableSecurityMember
2022-09-30
0001538217
us-gaap:CustomerConcentrationRiskMember
SRAX:MarketableSecuritiesMember
SRAX:TopTenMarketableSecurityMember
2022-01-01
2022-09-30
0001538217
SRAX:BigTokenIncMember
SRAX:SafeAgreementMember
2022-02-13
2022-02-15
0001538217
SRAX:BigTokenIncMember
SRAX:SafeAgreementMember
2022-09-30
0001538217
SRAX:ConvertibleDebenturesMember
2021-12-31
0001538217
us-gaap:WarrantMember
2021-12-31
0001538217
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0001538217
SRAX:ConvertibleDebenturesMember
2022-01-01
2022-09-30
0001538217
us-gaap:PreferredStockMember
2022-01-01
2022-09-30
0001538217
us-gaap:WarrantMember
2022-01-01
2022-09-30
0001538217
SRAX:ConvertibleDebenturesMember
2022-09-30
0001538217
us-gaap:WarrantMember
2022-09-30
0001538217
SRAX:DesignatedAssetsMember
2021-12-31
0001538217
SRAX:DesignatedAssetsMember
2022-01-01
2022-09-30
0001538217
SRAX:DesignatedAssetsMember
2022-09-30
0001538217
SRAX:DebenturesMember
2020-01-01
2020-12-31
0001538217
SRAX:PIPETechnologiesMember
2021-01-01
2021-12-31
0001538217
SRAX:ThirdPartyLendersAgreementMember
2022-06-30
0001538217
SRAX:ThirdPartyLendersAgreementMember
2022-01-01
2022-06-30
0001538217
SRAX:CVRAgreementMember
SRAX:InstitutionalInvestorMember
2022-09-30
0001538217
SRAX:CVRAgreementMember
SRAX:InstitutionalInvestorMember
2022-01-01
2022-09-30
0001538217
SRAX:CVRAgreementMember
2022-09-30
0001538217
SRAX:OIDConvertibleDebenturesMember
2020-06-30
0001538217
SRAX:OIDConvertibleDebenturesMember
2020-06-30
2020-06-30
0001538217
SRAX:OIDConvertibleDebenturesMember
2021-06-30
0001538217
SRAX:OIDConvertibleDebenturesMember
2022-01-01
2022-09-30
0001538217
SRAX:OIDConvertibleDebenturesMember
2020-06-01
2020-06-30
0001538217
SRAX:OIDConvertibleDebenturesMember
SRAX:SecuritiesPurchaseAgreementMember
SRAX:PlacementAgentMember
2022-01-01
2022-09-30
0001538217
SRAX:OIDConvertibleDebenturesMember
SRAX:SecuritiesPurchaseAgreementMember
SRAX:PlacementAgentMember
2022-09-30
0001538217
SRAX:OIDConvertibleDebenturesMember
SRAX:SecuritiesPurchaseAgreementMember
2022-09-30
0001538217
SRAX:SecuritiesPurchaseAgreementMember
SRAX:PlacementAgentMember
2022-01-01
2022-09-30
0001538217
SRAX:OIDConvertibleDebenturesMember
SRAX:SecuritiesPurchaseAgreementMember
2022-01-01
2022-09-30
0001538217
SRAX:HoldersMember
2022-07-01
0001538217
SRAX:HoldersMember
2022-07-01
2022-07-01
0001538217
SRAX:HoldersMember
2020-06-30
0001538217
SRAX:IssuanceDuringTheYearMember
2021-12-31
0001538217
SRAX:AmortizationMember
2022-03-31
0001538217
SRAX:IssuanceDuringTheYearMember
2022-03-31
0001538217
SRAX:AmortizationMember
2022-06-30
0001538217
SRAX:PrincipalAdjustmentsMember
2022-09-30
0001538217
SRAX:RepaymentsMember
2022-09-30
0001538217
SRAX:AmortizationMember
2022-09-30
0001538217
SRAX:BridgeNoteMember
2022-07-01
0001538217
SRAX:BridgeNoteMember
2022-07-01
2022-07-01
0001538217
SRAX:SeniorSecuredRevolvingCreditFacilityMember
SRAX:InstitutionalInvestorMember
2022-08-08
0001538217
SRAX:SeniorSecuredRevolvingCreditFacilityMember
SRAX:LenderMember
2022-08-08
0001538217
SRAX:SeniorSecuredRevolvingCreditFacilityMember
SRAX:LenderMember
SRAX:BridgeNoteMember
2022-08-08
0001538217
SRAX:SeniorSecuredRevolvingCreditFacilityMember
SRAX:LenderMember
srt:MaximumMember
2022-08-08
0001538217
SRAX:SeniorSecuredRevolvingCreditFacilityMember
SRAX:InstitutionalInvestorMember
2022-08-07
2022-08-08
0001538217
us-gaap:WarrantMember
SRAX:SecurityAgreementsMember
2020-06-30
2020-06-30
0001538217
us-gaap:WarrantMember
SRAX:SecurityAgreementsMember
2018-11-29
2018-11-29
0001538217
us-gaap:WarrantMember
SRAX:SecurityAgreementsMember
SRAX:TrancheOneMember
2018-11-29
2018-11-29
0001538217
us-gaap:WarrantMember
SRAX:SecurityAgreementsMember
2017-10-27
2017-10-27
0001538217
us-gaap:RevolvingCreditFacilityMember
2022-06-30
0001538217
us-gaap:RevolvingCreditFacilityMember
2022-07-01
2022-09-30
0001538217
us-gaap:RevolvingCreditFacilityMember
2022-09-30
0001538217
SRAX:ClassACommonStockMember
2022-09-30
0001538217
SRAX:ClassBCommonStockMember
2022-09-30
0001538217
SRAX:BoardOfDirectorsMember
SRAX:ClassACommonStockMember
2021-08-02
2021-08-31
0001538217
SRAX:ShareBuyBackProgramMember
2021-01-01
2021-12-31
0001538217
SRAX:ShareBuyBackProgramMember
2022-01-01
2022-06-30
0001538217
SRAX:ShareBuyBackProgramMember
2022-06-30
0001538217
SRAX:AtTheMarketSalesAgreementMember
2021-01-01
2021-12-31
0001538217
srt:ChiefExecutiveOfficerMember
SRAX:EquityCompensationPlansMember
2022-01-01
2022-01-02
0001538217
srt:ChiefExecutiveOfficerMember
SRAX:EquityCompensationPlansMember
2022-01-02
0001538217
SRAX:NonExecutiveEmployeesMember
SRAX:EquityCompensationPlansMember
2022-01-01
2022-01-31
0001538217
SRAX:NonExecutiveEmployeesMember
SRAX:EquityCompensationPlansMember
us-gaap:CommonStockMember
2022-01-01
2022-01-31
0001538217
us-gaap:WarrantMember
2022-07-31
0001538217
us-gaap:WarrantMember
2022-07-01
2022-07-31
0001538217
us-gaap:WarrantMember
2022-06-30
0001538217
us-gaap:WarrantMember
2022-04-01
2022-06-30
0001538217
us-gaap:SeriesAPreferredStockMember
srt:MaximumMember
2021-09-20
0001538217
us-gaap:SeriesAPreferredStockMember
2021-09-26
2021-09-27
0001538217
us-gaap:SeriesAPreferredStockMember
2021-09-27
0001538217
SRAX:ClassACommonStockMember
SRAX:EquityCompensationPlansMember
2022-09-30
0001538217
SRAX:NonemployeeDirectorsMember
SRAX:EquityCompensationPlansMember
2022-01-01
2022-01-03
0001538217
SRAX:NonemployeeDirectorsMember
SRAX:EquityCompensationPlansMember
2022-01-03
0001538217
SRAX:NonExecutiveEmployeesMember
SRAX:EquityCompensationPlansMember
SRAX:ClassACommonStockMember
2022-01-05
2022-01-06
0001538217
SRAX:NonExecutiveEmployeesMember
SRAX:EquityCompensationPlansMember
SRAX:ClassACommonStockMember
2022-01-06
0001538217
srt:ChiefExecutiveOfficerMember
SRAX:EquityCompensationPlansMember
2022-01-05
2022-01-06
0001538217
srt:ChiefExecutiveOfficerMember
SRAX:EquityCompensationPlansMember
2022-01-06
0001538217
SRAX:EmployeeMember
SRAX:EquityCompensationPlansMember
2022-01-05
2022-01-06
0001538217
SRAX:EmployeeMember
SRAX:EquityCompensationPlansMember
2022-01-06
0001538217
srt:ChiefFinancialOfficerMember
SRAX:EquityCompensationPlansMember
2022-01-05
2022-01-06
0001538217
srt:ChiefFinancialOfficerMember
SRAX:EquityCompensationPlansMember
2022-01-06
0001538217
SRAX:EmployeeMember
SRAX:EquityCompensationPlansMember
SRAX:ConditionalGrantMember
2022-01-05
2022-01-06
0001538217
SRAX:EmployeeMember
SRAX:EquityCompensationPlansMember
SRAX:ConditionalGrantMember
2022-01-06
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2020-06-30
2020-06-30
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2018-11-29
2018-11-29
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
us-gaap:ShareBasedCompensationAwardTrancheThreeMember
2018-11-29
2018-11-29
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
SRAX:ShareBasedCompensationAwardTrancheFourMember
2017-10-27
2017-10-27
0001538217
us-gaap:WarrantMember
2021-02-21
0001538217
SRAX:NewWarrantMember
2021-02-21
0001538217
us-gaap:WarrantMember
2021-02-20
2021-02-21
0001538217
SRAX:NewWarrantMember
2021-02-20
2021-02-21
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputExpectedTermMember
2022-01-03
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputExpectedTermMember
2022-01-06
0001538217
SRAX:StockOptionOneMember
us-gaap:MeasurementInputExpectedTermMember
2022-01-06
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-01-03
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-01-06
0001538217
SRAX:StockOptionOneMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-01-06
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputOptionVolatilityMember
2022-01-03
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputOptionVolatilityMember
2022-01-06
0001538217
SRAX:StockOptionOneMember
us-gaap:MeasurementInputOptionVolatilityMember
2022-01-06
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-01-03
0001538217
us-gaap:EmployeeStockOptionMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-01-06
0001538217
SRAX:StockOptionOneMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-01-06
0001538217
2021-01-01
2021-12-31
0001538217
SRAX:WarrantOneMember
2022-09-30
0001538217
SRAX:WarrantOneMember
2022-01-01
2022-09-30
0001538217
SRAX:WarrantTwoMember
2022-09-30
0001538217
SRAX:WarrantTwoMember
2022-01-01
2022-09-30
0001538217
SRAX:WarrantThreeMember
2022-09-30
0001538217
SRAX:WarrantThreeMember
2022-01-01
2022-09-30
0001538217
SRAX:WarrantFourMember
2022-09-30
0001538217
SRAX:WarrantFourMember
2022-01-01
2022-09-30
0001538217
SRAX:WarrantFiveMember
2022-09-30
0001538217
SRAX:WarrantFiveMember
2022-01-01
2022-09-30
0001538217
SRAX:WarrantSixMember
2022-09-30
0001538217
SRAX:WarrantSixMember
2022-01-01
2022-09-30
0001538217
us-gaap:WarrantMember
2022-01-01
2022-09-30
0001538217
SRAX:SequirePlatformRevenueMember
2022-07-01
2022-09-30
0001538217
SRAX:SequirePlatformRevenueMember
2021-07-01
2021-09-30
0001538217
SRAX:SequirePlatformRevenueMember
2022-01-01
2022-09-30
0001538217
SRAX:SequirePlatformRevenueMember
2021-01-01
2021-09-30
0001538217
SRAX:ConferenceRevenueMember
2022-07-01
2022-09-30
0001538217
SRAX:ConferenceRevenueMember
2021-07-01
2021-09-30
0001538217
SRAX:ConferenceRevenueMember
2022-01-01
2022-09-30
0001538217
SRAX:ConferenceRevenueMember
2021-01-01
2021-09-30
0001538217
SRAX:OtherRevenuesMember
2022-07-01
2022-09-30
0001538217
SRAX:OtherRevenuesMember
2021-07-01
2021-09-30
0001538217
SRAX:OtherRevenuesMember
2022-01-01
2022-09-30
0001538217
SRAX:OtherRevenuesMember
2021-01-01
2021-09-30
0001538217
SRAX:CustomerSecuritiesMember
2022-07-01
2022-09-30
0001538217
SRAX:CustomerSecuritiesMember
2021-07-01
2021-09-30
0001538217
SRAX:CustomerSecuritiesMember
2022-01-01
2022-09-30
0001538217
SRAX:CustomerSecuritiesMember
2021-01-01
2021-09-30
0001538217
SRAX:RevenueCashMember
2022-07-01
2022-09-30
0001538217
SRAX:RevenueCashMember
2021-07-01
2021-09-30
0001538217
SRAX:RevenueCashMember
2022-01-01
2022-09-30
0001538217
SRAX:RevenueCashMember
2021-01-01
2021-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:MarketableSecuritiesMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
SRAX:MarketableSecuritiesMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
SRAX:MarketableSecuritiesMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
SRAX:MarketableSecuritiesMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
us-gaap:FairValueInputsLevel1Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
us-gaap:FairValueInputsLevel2Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
us-gaap:FairValueInputsLevel3Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2022-09-30
0001538217
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
us-gaap:SeriesAPreferredStockMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
us-gaap:SeriesAPreferredStockMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
us-gaap:SeriesAPreferredStockMember
2022-09-30
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:MarketableSecuritiesMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
SRAX:MarketableSecuritiesMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
SRAX:MarketableSecuritiesMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
SRAX:MarketableSecuritiesMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:DesignatedAssetsMarketableSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
us-gaap:FairValueInputsLevel1Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
us-gaap:FairValueInputsLevel2Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
SRAX:ContractsAssetsMember
us-gaap:FairValueInputsLevel3Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2021-12-31
0001538217
us-gaap:SeriesAPreferredStockMember
us-gaap:PreferredStockMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001538217
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001538217
us-gaap:FairValueInputsLevel3Member
2021-12-31
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:CommonStockMember
2021-12-31
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-12-31
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:PreferredStockMember
2021-12-31
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:WarrantMember
2021-12-31
0001538217
us-gaap:FairValueInputsLevel3Member
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:PreferredStockMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:WarrantMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:CommonStockMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:PreferredStockMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:WarrantMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:CommonStockMember
SRAX:PutOptionPricingModelMember
us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember
srt:MinimumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:CommonStockMember
SRAX:PutOptionPricingModelMember
us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember
srt:MaximumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertiblePreferredStockMember
SRAX:PutOptionPricingModelMember
us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember
srt:MinimumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertiblePreferredStockMember
SRAX:PutOptionPricingModelMember
us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember
srt:MaximumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
us-gaap:ValuationTechniqueDiscountedCashFlowMember
us-gaap:MeasurementInputMaturityMember
srt:MinimumMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
us-gaap:ValuationTechniqueDiscountedCashFlowMember
us-gaap:MeasurementInputMaturityMember
srt:MaximumMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
us-gaap:ValuationTechniqueDiscountedCashFlowMember
us-gaap:MeasurementInputDiscountRateMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputMaturityMember
srt:MinimumMember
2022-01-01
2022-09-30
0001538217
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueOptionPricingModelMember
us-gaap:MeasurementInputMaturityMember
srt:MaximumMember
2022-01-01
2022-09-30
0001538217
2022-05-01
2022-05-31
0001538217
SRAX:AssetPurchaseAgreementMember
us-gaap:SubsequentEventMember
2023-02-03
0001538217
us-gaap:SeriesBPreferredStockMember
us-gaap:SubsequentEventMember
2023-02-02
2023-02-03
0001538217
us-gaap:CommonStockMember
us-gaap:SubsequentEventMember
2023-02-02
2023-02-03
0001538217
us-gaap:SubsequentEventMember
2023-02-03
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
2020-06-30
2020-06-30
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
2018-11-29
2018-11-29
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
SRAX:TrancheOneMember
2018-11-29
2018-11-29
0001538217
us-gaap:CommonStockMember
SRAX:SecurityAgreementsMember
2017-10-27
2017-10-27
0001538217
us-gaap:SubsequentEventMember
SRAX:LDMicroIncMember
2023-03-03
2023-03-03
0001538217
us-gaap:SubsequentEventMember
SRAX:LDMicroIncMember
2023-03-03
0001538217
us-gaap:SubsequentEventMember
2023-07-17
2023-07-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
SRAX:Segments
SRAX:Integer
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
one)
☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934
For
the Quarterly Period Ended September 30, 2022
or
☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission
File Number 001-37916
SRAX,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
45-2925231 |
(State
or other jurisdiction
of
incorporation or organization) |
|
(I.R.S.
Employer
Identification
No.) |
|
|
|
1014
S. Westlake Blvd., Suite 14-29
Westlake
Village, CA |
|
91361 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code (323) 205-6109
Securities
registered pursuant to Section 12(b) of the Act:
Class
A Common Stock, $0.001 par value |
|
SRAX |
|
N/A |
(Title
of each class) |
|
(Trading
Symbol) |
|
(Name
of each exchange on which registered) |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☐Yes ☒ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). ☐ Yes ☒ No
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
Non-accelerated
filer ☒ |
Smaller
reporting company ☒ |
Emerging
growth company ☐ |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
As
of October 20, 2023, there were 29,438,762 shares of Class A common stock were issued and outstanding.
SRAX,
Inc.
Table
of Contents
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING INFORMATION
The
statements contained in this Quarterly Report on Form 10-Q that are not purely historical are considered to be “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”). These forward-looking statements include, but are not limited to: any projections
of revenues, earnings, or other financial items; any statements of the strategies, plans and objectives of management for future operations;
any statements concerning proposed new products or developments; any statements regarding future economic conditions or performance;
any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the
words “may,” “will,” “estimate,” “intend,” “continue,” “believe,”
“expect” or “anticipate” and any other similar words. These statements represent our expectations, beliefs, anticipations,
commitments, intentions, and strategies regarding the future and include, but are not limited to, the risks and uncertainties described
in the sections of this Quarterly Report entitled Risk Factors and Management’s Discussion and Analysis of Financial Condition
and Results of Operations and those discussed in other documents we file with the United States Securities and Exchange Commission (“SEC”).
Readers are cautioned that actual results could differ materially from anticipated results or other expectations that are expressed in
forward-looking statements within this report. The forward-looking statements included in this report speak only as of the date hereof,
and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements.
We
urge you to read this entire Quarterly Report on Form 10-Q, including the “Risk Factors” section, the financial statements
and the related notes included therein as well as our Annual Report on Form 10-K for the year ended December 31, 2021, including the
“Risk Factors” section contained therein. As used in this Quarterly Report, unless context otherwise requires, the words
“we,” “us,” “our,” “the Company,” “SRAX,” “Registrant” refer
to SRAX, Inc. and its subsidiaries. Additionally, any reference to (i) “LD Micro” refer to the Company’s wholly owned
subsidiary, “LD Micro, Inc.” and the assets used in its operation. Also, any reference to “common share” or “common
stock,” refers to our $0.001 par value Class A common stock.
Any
reference to “BIGToken” and “BIGToken, Inc.” refer to the Company’s previously wholly owned subsidiary,
BIGToken, Inc. and the assets used in its operations which we transferred into Force Protection Video Equipment, Inc. (“FPVD”),
which became our majority owned subsidiary on February 4, 2021 and was subsequently disposed of on December 29, 2021.
Unless
otherwise stated, the information which appears on our web sites www.srax.com are not part of this report and are specifically not incorporated
by reference.
PART
1. FINANCIAL INFORMATION
ITEM
1. FINANCIAL STATEMENTS
SRAX,
INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
| |
September 30, 2022 | | |
| |
| |
(unaudited) | | |
December 31, 2021 | |
Assets | |
| | | |
| | |
CURRENT ASSETS | |
| | | |
| | |
Cash | |
$ | 116,000 | | |
$ | 1,348,000 | |
Accounts receivable, net | |
| 319,000 | | |
| 821,000 | |
Contracts receivable | |
| 499,000 | | |
| 844,000 | |
Marketable securities | |
| 2,918,000 | | |
| 15,617,000 | |
Designated assets for return of capital | |
| 221,000 | | |
| 3,925,000 | |
Prepaid expenses and other current assets | |
| 352,000 | | |
| 430,000 | |
TOTAL CURRENT ASSETS | |
| 4,425,000 | | |
| 22,985,000 | |
| |
| | | |
| | |
Marketable securities, net of current portion | |
| 18,203,000 | | |
| - | |
Notes receivable | |
| - | | |
| 935,000 | |
Property and equipment, net | |
| 121,000 | | |
| 114,000 | |
Intangible assets, net | |
| - | | |
| 1,443,000 | |
Right of use assets | |
| 162,000 | | |
| 257,000 | |
Other assets | |
| 8,000 | | |
| 36,000 | |
Goodwill | |
| 7,706,000 | | |
| 17,906,000 | |
TOTAL ASSETS | |
$ | 30,625,000 | | |
$ | 43,676,000 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 10,099,000 | | |
$ | 4,095,000 | |
Deferred revenue | |
| 12,862,000 | | |
| 12,859,000 | |
Other current liabilities | |
| 844,000 | | |
| 763,000 | |
Payroll protection loan | |
| 10,000 | | |
| 10,000 | |
OID convertible note(s) payable | |
| 1,094,000 | | |
| 1,164,000 | |
Senior secured revolving credit facility, net of OID | |
| 5,478,000 | | |
| - | |
Series A redeemable preferred stock | |
| 1,045,000 | | |
| 3,925,000 | |
TOTAL CURRENT LIABILITIES | |
| 31,432,000 | | |
| 22,816,000 | |
| |
| | | |
| | |
Right of use liability, net of current portion | |
| - | | |
| 114,000 | |
TOTAL LIABILITIES | |
| 31,432,000 | | |
| 22,930,000 | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
Series A preferred stock, $0.001 par value, 36,462,417 shares authorized, issued and outstanding, as liability classified at September 30, 2022 and December 31, 2021 | |
| - | | |
| - | |
Class A common stock, $0.001 par value, 250,000,000 shares authorized, 26,355,951 and 25,995,172 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | |
| 26,000 | | |
| 26,000 | |
Class B common stock, $0.0001 par value, 9,000,000 shares authorized and 0 issued and outstanding, at September 30, 2022 and December 31, 2021 | |
| - | | |
| - | |
Common
Stock Value | |
| | | |
| | |
| |
| | | |
| | |
Additional paid-in capital | |
| 52,643,000 | | |
| 51,075,000 | |
Accumulated deficit | |
| (53,476,000 | ) | |
| (30,355,000 | ) |
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | |
| (807,000 | ) | |
| 20,746,000 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY(DEFICIT) | |
$ | 30,625,000 | | |
$ | 43,676,000 | |
See
accompanying notes to unaudited condensed consolidated financial statements.
SRAX,
INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| |
| | |
| | |
| | |
| |
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2022 | | |
2021 | | |
2022 | | |
2021 | |
| |
| | |
| | |
| | |
| |
Revenues | |
$ | 5,309,000 | | |
$ | 6,888,000 | | |
$ | 20,530,000 | | |
$ | 18,963,000 | |
| |
| | | |
| | | |
| | | |
| | |
Cost and expenses | |
| | | |
| | | |
| | | |
| | |
Cost of revenues | |
| 942,000 | | |
| 3,354,000 | | |
| 9,181,000 | | |
| 8,541,000 | |
Employee related costs | |
| 2,185,000 | | |
| 1,892,000 | | |
| 5,840,000 | | |
| 5,347,000 | |
Selling, general and administrative | |
| 1,305,000 | | |
| 929,000 | | |
| 5,182,000 | | |
| 2,562,000 | |
Depreciation and amortization | |
| 17,000 | | |
| 251,000 | | |
| 403,000 | | |
| 710,000 | |
Total costs and expenses | |
| 4,449,000 | | |
| 6,426,000 | | |
| 20,606,000 | | |
| 17,160,000 | |
Income (loss) from operations | |
| 860,000 | | |
| 462,000 | | |
| (76,000 | ) | |
| 1,803,000 | |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Financing costs | |
| (2,377,000 | ) | |
| (528,000 | ) | |
| (3,954,000 | ) | |
| (10,098,000 | ) |
Impairment of goodwill | |
| - | | |
| - | | |
| (10,200,000 | ) | |
| - | |
Impairment of intangibles | |
| - | | |
| - | | |
| (1,481,000 | ) | |
| - | |
Loss on sale of fixed assets | |
| - | | |
| - | | |
| (47,000 | ) | |
| - | |
Realized gain (loss) on marketable securities | |
| (286,000 | ) | |
| 286,000 | | |
| (6,521,000 | ) | |
| 1,095,000 | |
Current period change in fair value of marketable securities | |
| (2,196,000 | ) | |
| (3,906,000 | ) | |
| 1,696,000 | | |
| (4,784,000 | ) |
Current period change in fair value of contract assets | |
| 22,000 | | |
| - | | |
| (1,491,000 | ) | |
| - | |
Realized loss on designated assets | |
| (904,000 | ) | |
| 2,000 | | |
| (1,803,000 | ) | |
| 2,000 | |
Current period change in fair value of designated assets | |
| 622,000 | | |
| (134,000 | ) | |
| (710,000 | ) | |
| (134,000 | ) |
Change in fair value of preferred stock | |
| 281,000 | | |
| 134,000 | | |
| 2,513,000 | | |
| 134,000 | |
Interest income | |
| - | | |
| 10,000 | | |
| 12,000 | | |
| 33,000 | |
Other income (expense) | |
| 159,000 | | |
| 1,130,000 | | |
| (1,058,000 | ) | |
| 1,145,000 | |
Total other expense, net | |
| (4,679,000 | ) | |
| (3,006,000 | ) | |
| (23,044,000 | ) | |
| (12,607,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Income tax expense | |
| - | | |
| - | | |
| - | | |
| - | |
Income (loss) from continuing operations | |
| (3,819,000 | ) | |
| (2,544,000 | ) | |
| (23,120,000 | ) | |
| (10,804,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Discontinued operations | |
| | | |
| | | |
| | | |
| | |
Loss before income tax expense | |
| - | | |
| (2,059,000 | ) | |
| - | | |
| (11,755,000 | ) |
Noncontrolling interest in discontinued operations | |
| - | | |
| 774,000 | | |
| - | | |
| 1,900,000 | |
Income tax expense | |
| - | | |
| - | | |
| - | | |
| - | |
Loss from discontinued operations | |
| - | | |
| (1,285,000 | ) | |
| - | | |
| (9,855,000 | ) |
Net income (loss) | |
$ | (3,819,000 | ) | |
$ | (3,829,000 | ) | |
$ | (23,120,000 | ) | |
$ | (20,659,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted income (loss) per share | |
| | | |
| | | |
| | | |
| | |
Continuing operations | |
$ | (0.14 | ) | |
$ | (0.10 | ) | |
$ | (0.88 | ) | |
$ | (0.48 | ) |
Discontinued operations | |
| - | | |
| (0.05 | ) | |
$ | - | | |
| (0.43 | ) |
Net income (loss) per share, basic and diluted | |
$ | (0.14 | ) | |
$ | (0.15 | ) | |
$ | (0.88 | ) | |
$ | (0.91 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares outstanding, basic and diluted | |
| 26,341,615 | | |
| 25,019,645 | | |
| 26,207,696 | | |
| 22,707,446 | |
See
accompanying notes to unaudited condensed consolidated financial statements.
SRAX,
INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| |
Preferred Stock | | |
Common Stock | | |
Additional paid-in | | |
Accumulated | | |
Non Controlling | | |
Stockholders’ Equity | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Interest | | |
(Deficit) | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance, December 31, 2021 | |
| - | | |
$ | - | | |
| 25,995,172 | | |
$ | 26,000 | | |
$ | 51,075,000 | | |
$ | (30,355,000 | ) | |
$ | - | | |
$ | 20,746,000 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 358,000 | | |
| - | | |
| - | | |
| 358,000 | |
Shares issued for exercise of employee options, net of taxes | |
| - | | |
| - | | |
| 91,981 | | |
| - | | |
| (101,000 | ) | |
| - | | |
| - | | |
| (101,000 | ) |
Net income | |
| | | |
| | | |
| - | | |
| - | | |
| - | | |
| 3,728,000 | | |
| | | |
| 3,728,000 | |
Balance, March 31, 2022 | |
| - | | |
| - | | |
| 26,087,153 | | |
| 26,000 | | |
| 51,332,000 | | |
| (26,627,000 | ) | |
| - | | |
| 24,731,000 | |
Share based compensation (benefit) | |
| - | | |
| - | | |
| - | | |
| - | | |
| (870,000 | ) | |
| - | | |
| - | | |
| (870,000 | ) |
Shares issued for exercise of warrants on a cashless basis | |
| - | | |
| - | | |
| 195,525 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Shares issued for exercise of warrants for cash | |
| | | |
| | | |
| 8,401 | | |
| - | | |
| 32,000 | | |
| - | | |
| - | | |
| 32,000 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (23,030,000 | ) | |
| - | | |
| (23,030,000 | ) |
Balance, June 30, 2022 | |
| - | | |
| - | | |
| 26,291,079 | | |
| 26,000 | | |
| 50,494,000 | | |
| (49,657,000 | ) | |
| - | | |
| 863,000 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 281,000 | | |
| - | | |
| - | | |
| 281,000 | |
Warrant modification expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,788,000 | | |
| - | | |
| - | | |
| 1,788,000 | |
Shares issued for loan breakup fee | |
| - | | |
| - | | |
| 33,000 | | |
| - | | |
| 80,000 | | |
| - | | |
| - | | |
| 80,000 | |
Shares issued for exercise of employee options | |
| | | |
| | | |
| 31,872 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Net income (loss) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,819,000 | ) | |
| - | | |
| (3,819,000 | ) |
Balance, September 30, 2022 | |
| - | | |
| - | | |
| 26,355,951 | | |
$ | 26,000 | | |
$ | 52,643,000 | | |
$ | (53,476,000 | ) | |
$ | - | | |
$ | (807,000 | ) |
See
accompanying notes to unaudited condensed consolidated financial statements.
SRAX,
INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (Continued)
(Unaudited)
| |
Preferred Stock | | |
Common Stock | | |
Additional paid-in | | |
Accumulated | | |
Non Controlling | | |
Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Interest | | |
Equity | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance, December 31,2020 | |
| - | | |
$ | - | | |
| 16,145,778 | | |
$ | 16,000 | | |
$ | 69,551,000 | | |
$ | (50,342,000 | ) | |
$ | - | | |
$ | 19,225,000 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 253,000 | | |
| - | | |
| - | | |
| 253,000 | |
Shares issued for cash | |
| - | | |
| - | | |
| 53,616 | | |
| - | | |
| 284,000 | | |
| - | | |
| - | | |
| 284,000 | |
Conversion of convertible debt to equity | |
| - | | |
| - | | |
| 2,041,551 | | |
| 2,000 | | |
| 3,445,000 | | |
| - | | |
| - | | |
| 3,447,000 | |
Shares issued for exercise of warrants | |
| - | | |
| - | | |
| 4,945,320 | | |
| 5,000 | | |
| 12,215,000 | | |
| - | | |
| - | | |
| 12,220,000 | |
Warrants issued as inducement to exercise warrants | |
| - | | |
| - | | |
| - | | |
| - | | |
| 7,737,000 | | |
| - | | |
| - | | |
| 7,737,000 | |
Establishment of noncontrolling interest of FVPD | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (95,000 | ) | |
| (95,000 | ) |
Warrants issued by FVPD for SRAX, Inc. debenture holders | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 885,000 | | |
| 885,000 | |
Series B convertible preferred stock issued by FPVD | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 5,775,000 | | |
| 5,775,000 | |
Beneficial conversion feature FPVD series B convertible preferred stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 5,775,000 | | |
| 5,775,000 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (11,090,000 | ) | |
| (854,000 | ) | |
| (11,944,000 | ) |
Balance, March 31,2021 | |
| - | | |
| - | | |
| 23,186,265 | | |
| 23,000 | | |
| 93,485,000 | | |
| (61,432,000 | ) | |
| 11,486,000 | | |
| 43,562,000 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 253,000 | | |
| - | | |
| - | | |
| 253,000 | |
Conversion of convertible debt to equity | |
| - | | |
| - | | |
| - | | |
| - | | |
| 701,000 | | |
| - | | |
| - | | |
| 701,000 | |
Shares issued for exercise of warrants | |
| - | | |
| - | | |
| 350,000 | | |
| - | | |
| 3,575,000 | | |
| - | | |
| - | | |
| 3,575,000 | |
Series B convertible preferred stock issued by FPVD | |
| - | | |
| - | | |
| 1,310,198 | | |
| 1,000 | | |
| - | | |
| - | | |
| 85,000 | | |
| 86,000 | |
Beneficial conversion feature FPVD series B convertible preferred stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 85,000 | | |
| 85,000 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (5,740,000 | ) | |
| (272,000 | ) | |
| (6,012,000 | ) |
Balance, June 30, 2021 | |
| - | | |
| - | | |
| 24,846,463 | | |
| 24,000 | | |
| 98,014,000 | | |
| (67,172,000 | ) | |
| 11,384,000 | | |
| 42,250,000 | |
Balance | |
| - | | |
| - | | |
| 24,846,463 | | |
| 24,000 | | |
| 98,014,000 | | |
| (67,172,000 | ) | |
| 11,384,000 | | |
| 42,250,000 | |
Share based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 251,000 | | |
| - | | |
| - | | |
| 251,000 | |
Conversion of convertible debt to equity | |
| - | | |
| - | | |
| 730,616 | | |
| 1,000 | | |
| 1,824,000 | | |
| - | | |
| - | | |
| 1,825,000 | |
Shares issued for exercise of warrants | |
| - | | |
| - | | |
| 53,668 | | |
| - | | |
| 157,000 | | |
| - | | |
| - | | |
| 157,000 | |
Dividends on preferred stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| (6,387,000 | ) | |
| - | | |
| - | | |
| (6,387,000 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,829,000 | ) | |
| (774,000 | ) | |
| (4,603,000 | ) |
Net Income (loss) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,829,000 | ) | |
| (774,000 | ) | |
| (4,603,000 | ) |
Balance, September 30, 2021 | |
| - | | |
$ | - | | |
| 25,630,747 | | |
$ | 25,000 | | |
$ | 93,859,000 | | |
$ | (71,001,000 | ) | |
$ | 10,610,000 | | |
$ | 33,493,000 | |
Balance | |
| - | | |
$ | - | | |
| 25,630,747 | | |
$ | 25,000 | | |
$ | 93,859,000 | | |
$ | (71,001,000 | ) | |
$ | 10,610,000 | | |
$ | 33,493,000 | |
See
accompanying notes to unaudited condensed consolidated financial statements.
SRAX,
INC. AND SUBSIDIARIES
CONDESNED
CONSOLIDATED STATEMENTS OF CASH FLOW
(Unaudited)
| |
| | |
| |
| |
Nine months ended September 30, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
Cash Flows From Operating Activities: | |
| | | |
| | |
Net loss | |
$ | (23,120,000 | ) | |
$ | (20,659,000 | ) |
Less: net loss from discontinued operations, net of tax | |
| - | | |
| 9,855,000 | |
Loss from continuing operations | |
| (23,120,000 | ) | |
| (10,804,000 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Impairment of goodwill | |
| 10,200,000 | | |
| - | |
Impairment of intangibles | |
| 1,481,000 | | |
| - | |
Loss on sale of fixed assets | |
| 47,000 | | |
| - | |
Realized gain (loss) on marketable securities | |
| 6,521,000 | | |
| (1,095,000 | ) |
Current period change in fair value of marketable securities | |
| (1,696,000 | ) | |
| 4,784,000 | |
Current period change in fair value of contract assets | |
| 1,491,000 | | |
| - | |
Realized gain (loss) on designated assets | |
| 1,803,000 | | |
| (2,000 | ) |
Current period change in fair value of designated assets | |
| 710,000 | | |
| 134,000 | |
Change in fair value of preferred stock | |
| (2,513,000 | ) | |
| (134,000 | ) |
Warrant modification expense | |
| 1,788,000 | | |
| - | |
Stock based compensation (benefit) | |
| (231,000 | ) | |
| 757,000 | |
Interest income | |
| - | | |
| (33,000 | ) |
Amortization of debt discount | |
| 154,000 | | |
| 799,000 | |
Loss on settlement of note receivable | |
| 35,000 | | |
| - | |
Fair value of warrants issued by FPVD to SRAX, Inc. debenture holders | |
| - | | |
| 885,000 | |
Forgiveness of payroll protection program loan | |
| - | | |
| (1,116,000 | ) |
Warrant inducement expense | |
| - | | |
| 7,737,000 | |
Net provision for (recovery of) bad debts | |
| (60,000 | ) | |
| (305,000 | ) |
Depreciation expense | |
| 53,000 | | |
| 61,000 | |
Amortization of intangibles | |
| 350,000 | | |
| 1,061,000 | |
Amortization of right of use assets | |
| 95,000 | | |
| - | |
Non-cash financing expense | |
| 237,000 | | |
| 213,000 | |
Changes in operating assets and liabilities | |
| | | |
| | |
Accounts receivable, net | |
| 563,000 | | |
| 1,537,000 | |
Prepaid expenses and other current assets | |
| 105,000 | | |
| (631,000 | ) |
Contracts receivable | |
| (1,146,000 | ) | |
| - | |
Designated assets for return of capital | |
| 685,000 | | |
| - | |
Accounts payable and accrued expenses | |
| 6,002,000 | | |
| 370,000 | |
Deferred revenue | |
| (13,711,000 | ) | |
| (16,582,000 | ) |
Other current liabilities | |
| 1,573,000 | | |
| (396,000 | ) |
Right of use liability | |
| (96,000 | ) | |
| (15,000 | ) |
Net cash used in continuing operations | |
| (8,680,000 | ) | |
| (12,775,000 | ) |
Net cash used in discontinued operations | |
| - | | |
| (5,895,000 | ) |
Net cash used in operating activities | |
| (8,680,000 | ) | |
| (18,670,000 | ) |
Cash flows from investing activities: | |
| | | |
| | |
Proceeds from sale of marketable securities | |
| 3,385,000 | | |
| 7,144,000 | |
Proceeds from note receivable | |
| 900,000 | | |
| - | |
Deferred payments to LD Micro | |
| - | | |
| (3,004,000 | ) |
Proceeds from the sale of designated assets | |
| 506,000 | | |
| - | |
Acquisition of property and equipment | |
| (108,000 | ) | |
| (97,000 | ) |
Acquisition of intangible assets | |
| (388,000 | ) | |
| (541,000 | ) |
Other assets | |
| - | | |
| (33,000 | ) |
Net cash from continuing operations | |
| 4,295,000 | | |
| 3,040,000 | |
Net cash from discontinued operations | |
| - | | |
| 955,000 | |
Net cash from investing activities | |
| 4,295,000 | | |
| 3,995,000 | |
Cash flows from financing activities: | |
| | | |
| | |
Preferred stock distributions | |
| (365,000 | ) | |
| - | |
Proceeds from issuance of common stock | |
| - | | |
| 284,000 | |
Payments of taxes related to settlement of restricted stock units | |
| (101,000 | ) | |
| - | |
Proceeds from the exercise of warrants | |
| 32,000 | | |
| 15,953,000 | |
Proceeds from factoring facilities | |
| 5,362,000 | | |
| - | |
Repayments of factoring facilities | |
| (6,184,000 | ) | |
| - | |
Repayments of OID convertible notes payable | |
| (277,000 | ) | |
| - | |
Proceeds from senior secured revolving credit facility | |
| 4,686,000 | | |
| - | |
Net cash from continuing operations | |
| 3,153,000 | | |
| 16,237,000 | |
Net cash from discontinued operations | |
| - | | |
| 4,810,000 | |
Net cash from financing activities | |
| 3,153,000 | | |
| 21,047,000 | |
SRAX,
INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOW (Continued)
(Unaudited)
| |
Nine months ended September 30, | |
| |
2022 | | |
2021 | |
Net (decrease) increase in cash from continuing operations | |
| (1,232,000 | ) | |
| 6,502,000 | |
Net decrease in cash from discontinued operations | |
| - | | |
| (130,000 | ) |
Cash, beginning of period | |
| 1,348,000 | | |
| 451,000 | |
Cash, end of period | |
$ | 116,000 | | |
$ | 6,823,000 | |
| |
| | | |
| | |
Supplemental schedule of cash flow information | |
| | | |
| | |
Cash paid for interest | |
$ | 77,000 | | |
$ | 14,000 | |
Cash paid for taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Supplemental schedule of noncash investing and financing activities | |
| | | |
| | |
Fair value of marketable securities received for revenue contracts, net | |
$ | 15,943,000 | | |
$ | 26,564,000 | |
Convertible notes converted into shares | |
$ | - | | |
$ | 6,423,000 | |
Designation of marketable securities for dividend distributions | |
$ | - | | |
$ | 6,387,000 | |
Dividends on preferred stock | |
$ | - | | |
$ | 6,387,000 | |
See
accompanying notes to unaudited condensed consolidated financial statements.
SRAX,
INC. AND SUBSIDIARIES
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2022
NOTE
1 – ORGANIZATION AND LIQUIDITY
Organization
SRAX,
Inc. (“SRAX”, “we”, “us”, “our” or the “Company”) is a Delaware corporation
formed on August 2, 2011. SRAX is headquartered in Westlake Village, California but operates as a distributed virtual Company. As of
September 30, 2022, the unaudited Condensed Consolidated Financial Statements consist of SRAX and its wholly owned subsidiary LD Micro,
Inc. (“LD Micro”).
SRAX
is a technology firm focused on enhancing communications between public companies and their shareholders and investors. The Company currently
has one reportable and operating segment, which consists of one reporting unit consisting of two distinct business units:
|
● |
The
unique SaaS platform, Sequire provides users many features which allow issuers to track their shareholders’ behaviors and trends,
then use data-driven insights to engage with shareholders across marketing channels. |
|
|
|
|
● |
Through
LD Micro, the Company organizes and hosts investor conferences within the micro and small- cap markets, and plans to create several
more niche events for the investor community. |
Each
of SRAX’s business units deliver valuable insights that assist the Company’s clients with their investor relations and communications
initiatives.
On
February 4, 2021, the Company acquired FPVD through a reverse acquisition involving BIG Token, Inc. On December 29, 2021, the Company
deconsolidated the Company’s majority owned subsidiary BIG Token, Inc. (“BIGToken”) formerly known as Force Protection
Video Equipment Corporation (or “FPVD”). See Note 3 –Discontinued Operations.
On
March 3, 2023, the Company divested the LD Micro subsidiary.
Liquidity
and Capital Resources
The
Company has incurred significant losses since its inception and has not demonstrated an ability to generate cash in excess of its operating
expenses for a sustained period of time. As of September 30, 2022, the Company had cash of $116,000 which is not sufficient to fund the
Company’s planned operations through one year after the date the unaudited Condensed Consolidated Financial Statements are issued.
These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year after the
date that the unaudited Condensed Consolidated Financial Statements are issued.
The
unaudited Condensed Consolidated Financial Statements do not include any adjustments that might be necessary if the Company is unable
to continue as a going concern. Accordingly, the unaudited Condensed Consolidated Financial Statements have been prepared on a basis
that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities
and commitments in the ordinary course of business.
In
making this assessment, the Company performed a comprehensive analysis of current circumstances including: its financial position, cash
flow and cash usage forecasts, and obligations and debts. Although management has a long history of successful capital raises, the analysis
used to determine the Company’s ability as a going concern does not include cash sources outside the Company’s direct control
that management expects to be available within the next 12 months.
The
Company expects that its existing cash, accounts receivable and sale of marketable securities as of September 30, 2022, will not be sufficient
to enable it to fund the anticipated level of operations through one year from the date these financial statements are issued. The Company
projects the sale of its marketable security holding will represent a substantial portion of the cash required for operations for the
foreseeable future. The Company’s sales of marketable securities are primarily through sale transactions that qualify for exemptions
pursuant to Rule 144 of the Securities Act of 1933. The conditions required to be met to qualify for the exemptions under Rule 144 are
often difficult to predict, making it difficult to predict the timing of the associated cash flows from the sales of these securities.
The Company’s holdings of marketable securities are subject to risks and uncertainties such as fluctuations in pricing in the primary
market, and legal restrictions that create uncertainty around realization and timing of cash flows.
The
Company anticipates raising additional capital through the private and public sales of its equity or debt securities and selling its
marketable securities, or a combination thereof. Although management believes that such capital sources will be available, there can
be no assurances that financing will be available when needed in order to allow the Company to continue its operations, or if available,
on terms acceptable to it. If the Company does not raise sufficient capital in a timely manner, among other things, it may be forced
to scale back its operations or cease operations altogether.
NOTE
2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
accompanying Condensed Consolidated Financial Statements and notes thereto are unaudited. The unaudited interim Condensed Consolidated
Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)
and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Certain information
and note disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The December
31, 2021 Condensed Consolidated Balance Sheet was derived from financial statements but does not include all disclosures required by
GAAP. These interim unaudited Condensed Consolidated Financial Statements, in the opinion of management, reflect all normal recurring
adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim nine-month
periods ended September 30, 2022 and 2021. The results for the nine months ended September 30, 2022 are not necessarily indicative of
the results to be expected for the full year ending December 31, 2022 or for any future period.
These
unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial
Statements and the notes thereto for the year ended December 31, 2021, included in the Company’s annual report on Form 10-K filed
with the SEC.
Principles
of Consolidation
The
unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All material
intercompany transactions and balances have been eliminated in consolidation.
Reclassification
Certain
prior period amounts have been reclassified to conform to current period presentation.
Use
of Estimates
The
unaudited Condensed Consolidated Financial Statements have been prepared in conformity with GAAP and require management of the Company
to make estimates and assumptions in the preparation of these unaudited Condensed Consolidated Financial Statements that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and assumptions.
The
most significant areas that require management judgment and which are susceptible to possible change in the near term include, among
other items, the Company’s revenue recognition, valuation of marketable investment securities, stock-based compensation, income
taxes, purchase price for acquisitions, goodwill, other intangible assets, and the valuation of redemption features and other assets
and liabilities.
Fair
Value of Financial Instruments
The
accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair
value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal,
most advantageous market for the specific asset or liability.
In
determining fair value, the Company uses various valuation techniques. A fair value hierarchy for inputs is used in measuring fair value.
It maximizes observable inputs and minimizes unobservable inputs. Valuation techniques consistent with the market or income approach
are used to measure fair value. The fair value hierarchy is categorized into three levels:
|
● |
Level
1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
to access; |
|
|
|
|
● |
Level
2 - Valuations based on inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly;
and |
|
|
|
|
● |
Level
3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
Fair
value is a market-based measure that is based on assumptions of prices and inputs considered from the perspective of a market participant
on the measurement date.
The
availability of valuation techniques and observable inputs can vary from investment to investment and are affected by a wide variety
of factors. The determination of fair value requires prudent judgment. Due to the inherent uncertainty of valuation, estimated values
may be materially different from values were a ready market available. Inputs used to measure fair value may fall into different levels
of the fair value hierarchy. In such cases, the item being valued is classified based on the hierarchy category of the lowest significant
level input to the fair value measurement. See Note 12 Fair Value of Financial Instruments.
Cash
The
Company considers all short-term highly liquid investments with a remaining maturity at the date of purchase of three months or less
to be cash equivalents. Cash is recorded at cost, which approximates its fair value. The Company did not have any cash equivalents as
of September 30, 2022 and December 31, 2021. The Company maintains its cash in banks insured by the Federal Deposit Insurance Corporation
(“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes
this risk by placing its cash deposits with major financial institutions. As of September 30, 2022 and December 31, 2021, the Company
had $0 and $1,098,000 in excess of the federal insurance limit, respectively.
Marketable
Securities
Marketable
Securities consist of debt and equity securities. The Company accounts for marketable equity securities, including convertible preferred
shares at fair value pursuant to ASC 321 Investments – Equity Securities, and marketable debt securities at fair value in accordance
with ASC 320 – Investments Debt Securities. Marketable securities were approximately $21.1 million and $15.6 million as of September
30, 2022 and December 31, 2021, respectively.
Accounts
Receivable
Credit
is extended to customers based on an evaluation of their financial condition and other factors, and the Company usually does not require
collateral. Management periodically assesses the Company’s accounts receivable and, if necessary, establishes an allowance for
estimated uncollectible amounts. Accounts determined to be uncollectible are charged to operations when that determination is made. The
allowance for doubtful accounts was approximately $69,000 and $130,000 as of September 30, 2022 and December 31, 2021, respectively.
Concentration
of Credit and Significant Customer Risk
Financial
instruments that potentially subject the Company to concentration of credit risk consist of cash, accounts receivable and notes receivable.
Cash is deposited with financial institutions within the United States. The balances maintained at these financial institutions are generally
more than the FDIC insurance limits. The Company has not experienced any loss on these accounts.
As
of September 30, 2022, the Company did not have any customers with accounts receivable balances representing greater than 10% of the
Company’s aggregate accounts receivable. As of December 31, 2021, the Company had one customer with an accounts receivable balance
of approximately 11%.
For
the nine months ended September 30, 2022 and 2021, the Company had no customers that account for a significant percentage of total revenues.
Goodwill
and Intangible assets
Intangible
assets consist of (i) goodwill, intellectual property, trademarks, trade names and non-compete agreements acquired in business combinations
and capitalized software development costs. Other than goodwill and trademarks, intangible assets are stated at cost less accumulated
amortization. Amortization is provided for on the straight-line basis over the estimated useful lives of the assets of five years.
Impairment
of Goodwill, Intangible Assets and Other Long-lived Assets
Management
evaluates the recoverability of the Company’s definitive lived intangible assets and other long-lived assets when events or circumstances
indicate a potential impairment exists. Events and circumstances considered by the Company in determining whether the carrying value
of identifiable intangible assets and other long-lived assets may not be recoverable include, but are not limited to: significant changes
in performance relative to expected operating results; significant changes in the use of the assets; significant negative industry or
economic trends; a significant decline in the Company’s stock price for a sustained period of time; and changes in the Company’s
business strategy. In determining if impairment exists, the Company estimates the undiscounted cash flows to be generated from the use
and ultimate disposition of these assets. If impairment is indicated based on a comparison of the assets’ carrying values and the
undiscounted cash flows, the impairment loss is measured as the amount by which the carrying amount of the assets exceeds the fair value
of the assets.
Management
evaluates the recoverability of the Company’s goodwill annually at December 31 or more often as events or circumstances indicate
the fair value of a reporting unit is below its carrying value. The Company has determined that it operates as a single reporting unit
for the purposes of conducting this goodwill impairment assessment. If the fair value of a reporting unit is less than its carrying value,
an impairment loss is recorded to the extent that implied fair value of the goodwill within the reporting unit is less than its carrying
value.
An
impairment in the amount of $10,200,000 to goodwill, and $1,481,000 to intangible assets was recognized for the nine months ended September
30, 2022. The impairment was determined as the carrying amount of goodwill exceeded its implied fair value based on a discounted cash
flow projection. The transition to accepting only cash as compensation for services will cause a significant decrease in revenue and
cash collections, which has a material negative impact on the discounted cash flow projection. No impairments of goodwill or other long-lived
assets have been recognized for the nine months ended September 30, 2021.
Revenue
Recognition
The
Company recognizes revenues upon the satisfaction of its performance obligation(s) (upon transfer of control of promised goods or services
to its customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services.
The Company determines the amount of revenue to be recognized through the application of the five-step process as follows:
|
1) |
identification
of contracts with customers; |
|
2) |
identification
of the distinct performance obligations in the contract; |
|
3) |
determination
of the transaction price of the contract; |
|
4) |
allocation
of transaction price among the performance obligations in the contract; and |
|
5) |
recognition
of revenue as performance obligations are satisfied. |
The
Company has elected the following practical expedients allowed in accounting for its revenue recognition:
|
● |
not
adjusting contract consideration for the effects of significant financing components if the period between transfer or service and
customer payment is expected to be less than one year; |
|
● |
not
assessing performance obligations if they are immaterial in the context of the contract; |
|
● |
excluding
sales and similar taxes from the transaction price; and |
|
● |
not
disclosing the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. |
The
Company generates revenue primarily from its Sequire SaaS platform and its LD Micro subsidiary. Specifically, the Sequire SaaS platform
related revenue consists of (i) licensing subscriptions to access the platform, (ii) managed services involving data and marketing initiatives
and (iii) ancillary data supplementing the use of the platform. LD Micro revenues consist of attendee fees and event sponsorship fees
related investor conferences organized and hosted by the Company.
Sequire
SaaS platform
Sequire
SaaS platform agreements are typically for a period of 12-months and provide for monthly or annual payments in advance.
Prior
to 2023 many of the Sequire SaaS platform agreements provide customers the ability to pay for the services with the issuance of the customers’
securities including common stock. The amount of consideration for these contracts is based on the estimated fair value of the underlying
securities on the contract date. See “Fair Value of Financial Instruments” for details over the calculation of fair value.
In 2023 the Company transitioned to accepting only cash as compensation for services. As we transition to accepting only cash as compensation
for services there will be a significant decrease in Sequire revenue.
When
Sequire SaaS platform contracts contain multiple performance obligations, transaction consideration is allocated to each individual performance
obligation based on a relative Stand-Alone Selling Price (“SSP,”) basis. The Company determines SSP based on the price at
which the performance obligation would be sold separately.
Subscription
revenue is generally non-refundable regardless of the actual use and is recognized ratably over the non-cancellable contract term beginning
on the commencement date of each contract, which is the date the Company’s service is first made available to customers.
Managed
Services and Ancillary Data revenue is typically recognized using an output measure of progress by looking at the time elapsed as the
contracts generally provide the customer equal benefit throughout the contract period because the Company transfers control evenly by
providing a stand-ready service.
LD
Micro - Conference Revenue
LD
Micro agreements cover a specific event and provide for payment in advance or at the time of the event. Conference revenue from attendee
fees and sponsorship fees is recognized at the time of the event (i.e., at a point-in-time).
Contracts
Receivable
Contracts
receivable represents amounts for which non-cancellable revenue contracts with customers have been finalized but the payment in the form
of securities issued by the customer have not been received by the Company.
Deferred
Revenue
Deferred
revenue resulting from amounts billed to, or cash received from, customers in advance of the Company satisfying its performance obligation
and recognizing the applicable revenue.
Preferred
stock
Preferred
stock liability represents amounts payable to holders of the Preferred Stock Series A shares upon the eventual liquidation of assets
designated for the sole purpose of paying dividends. Accordingly, the Company classified the Series A Preferred Shares as liability instruments
because in-substance, they represent a right to the payment of dividends upon the liquidation of specified assets, are automatically
returnable to the Company after the payments are made and feature no rights to further equity or residual interests in the Company. The
Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Preferred Stock states dividend shall be paid
conditioned upon, and subject to a determination by the Board that a distribution is not prohibited pursuant to applicable provisions
of the DGCL or other applicable law.
Costs
to Obtain or Costs to Fulfill a Contract
The
Company has no costs that qualify as costs to obtain or costs to fulfill customer contracts.
Net
Loss Per Share
Basic
earnings per share is calculated by dividing net loss by the weighted-average number of shares outstanding during the period. Diluted
loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding, after giving effect to
all potentially dilutive common shares outstanding during the period. For periods with a net loss, basic and diluted earnings per share
are the same, in that a potentially common stock equivalent would have the effect of being anti-dilutive in the computation of net loss
per share. The number of potentially outstanding dilutive common shares excluded from the diluted net loss per calculation, as they were
anti-dilutive were 911,868 for three and the nine months ended September 30, 2022, and 11,867,520 for the three months and nine months
ended September 30, 2021.
Recent
Accounting Pronouncements
In
June 2022, the FASB issued Accounting Standards Update (“ASU”) ASU 2022-03 (“Fair Value Measurements”),
which clarifies the guidance in ASC 820 (“Fair Value Measurement”) (“ASC 820”), (1) when measuring the fair value
of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative
example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured
at fair value in accordance with ASC 820. The adoption did not impact the Company’s financial position, results of operations or
cash flows.
Recent
Accounting Pronouncements Not Yet Adopted
In
August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, Debt-Debt with Conversion and Other
Options which simplifies the accounting for convertible instruments by removing certain separation models (including the cash conversion
model and the beneficial conversion feature model) for convertible instruments. As a result, for convertible instruments with conversion
features that are not required to be accounted for as derivative instruments or that do not result in substantial premiums accounted
for as paid-in capital, the embedded conversion features are no longer separated from the host contract. Consequently, a convertible
debt instrument will be accounted for as a single liability measured at its amortized cost, and convertible preferred stock will be accounted
for as a single equity instrument measured at its historical cost as long as no other features require bifurcation and recognition as
derivatives. This guidance is effective on a modified retrospective or full retrospective basis for fiscal years beginning after December
15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact on the consolidated financial
statements.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) addressing accounting for credit
losses on financial instruments, which is designed to provide financial statement users with more information about the expected credit
losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. When determining
such expected credit losses, the guidance requires companies to apply a methodology that reflects expected credit losses and requires
consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance is effective
on a modified retrospective basis for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.
The Company is currently evaluating the impact on the consolidated financial statements.
The
Company’s management reviewed all recently issued ASU’s not yet adopted by the Company and does not believe the future adoptions
of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results
of its operations.
NOTE
3 – DISCONTINUED OPERATIONS
Background
On
February 4, 2021, the Company completed a share exchange agreement (“Exchange Agreement”) with FPVD. As part of the Exchange
Agreement the Company transferred all of the BIGToken assets and 100% of the issued and outstanding shares of BIGToken for 149,562,566,534
shares of FPVD’s common stock and 5,000,000 shares of FPVD’s series A preferred stock. The Company accounted for the transaction
as a reverse capitalization and resulted in reducing the Company’s ownership in BIGToken from 100% to 88.9% and establishment of
a non-controlling interest. Subsequently, FPVD was renamed BIGToken.
Deconsolidation
On
December 29, 2021, BIGToken (formerly FPVD) completed a merger transaction with BritePool, Inc. (“BritePool”) (the “Merger”)
resulting in the Company’s ownership in BIGToken being reduced from 66% to approximately 4.99%. As a result of the Merger, BIGToken
issued 183,445,351,631 shares of its common stock (“Acquisition Shares”) for all of the issued and outstanding equity shares
of BritePool. On December 29, 2021, as a condition for the closing of the Merger, the Company exchanged 149,562,566,534 shares of BIGToken
common stock for 242,078 shares of BIGToken’s Series D Convertible Preferred Stock (“Series D Stock”) (the “Exchange”).
Simultaneously with the Exchange, the Company converted 22,162 shares of the Series D Stock into 13,692,304,136 shares of BIGToken’s
common stock, or approximately 4.99% of the issued and outstanding shares of BIGToken’s common stock.
Subsequent
to the transaction, the Company now owns 220,000 shares of BIGToken’s series D convertible, non-redeemable, non-voting preferred
stock and 13,692,304,136 shares of its common stock. As a result of the transaction, the Company no longer has a controlling financial
interest in BIGToken and deconsolidated BIGToken effective December 29, 2021, recognizing a loss
of $10.7 million as follows:
SCHEDULE
OF DECONSOLIDATION OF BUSINESS
Consideration | |
Amount | |
Fair value of Series D Stock and Common Stock | |
$ | 31,000 | |
Carrying amount of non-controlling interests of BIGToken | |
| 6,045,000 | |
Previous equity adjustments of non-controlling interest | |
| (12,510,000 | ) |
Total | |
| (6,434,000 | ) |
| |
| | |
Book basis of investment in BIGToken | |
| 4,250,000 | |
Loss on disposal of subsidiary | |
$ | (10,684,000 | ) |
The
Company determined the Series D Stock would be classified as a Level 3 asset as there is no observable market for quoted market price
for an identical asset. The Company engaged an independent third-party valuation expert to estimate the fair value of the Series D Stock.
The
financial results of BIGToken are presented as loss from discontinued operations, net of income taxes and net of income attributable
to non-controlling interests on the Company’s unaudited Condensed Consolidated Statement of Operations for the three and nine months
ended September 30, 2021. The historical Condensed Consolidated Statement of Cash Flows has also been revised to reflect the effect of
the deconsolidation. The following table presents the financial results of BIGToken:
SCHEDULE
OF ASSET AND LIABILITIES INCOME FROM DISCONTINUE OPERATIONS
| |
Three Months Ended September 30, 2021 | | |
Nine Months Ended September 30, 2021 | |
Revenues | |
$ | 765,000 | | |
$ | 2,469,000 | |
| |
| | | |
| | |
Cost and expenses | |
| | | |
| | |
Cost of revenues | |
| 207,000 | | |
| 715,000 | |
Employee related costs | |
| 988,000 | | |
| 2,649,000 | |
Marketing and selling expenses | |
| 372,000 | | |
| 861,000 | |
Platform costs | |
| 78,000 | | |
| 245,000 | |
Depreciation and amortization | |
| 101,000 | | |
| 412,000 | |
General and administrative expenses | |
| 1,078,000 | | |
| 3,483,000 | |
Total cost and expenses | |
| 2,824,000 | | |
| 8,365,000 | |
Loss from operations | |
| (2,059,000 | ) | |
| (5,896,000 | ) |
| |
| | | |
| | |
Other expense | |
| | | |
| | |
Deemed dividend on preferred stock | |
| - | | |
| (5,859,000 | ) |
Total other expense | |
| - | | |
| (5,859,000 | ) |
| |
| | | |
| | |
Loss from discontinued operations before income tax expense | |
| (2,059,000 | ) | |
| (11,755,000 | ) |
Income tax expense | |
| - | | |
| - | |
Loss from discontinued operations | |
$ | (2,059,000 | ) | |
$ | (11,755,000 | ) |
NOTE
4 – NOTES RECEIVABLE
In
October 2020, the Company entered into unit redemption agreements with two counterparties providing for the counterparties to repurchase
from the Company units of the counterparty’s securities owned by the Company. Pursuant to the redemption agreements, the counterparties
repurchased the units for a combined repurchase price of $8 million with $7 million being paid on closing and the additional $1 million
being deferred and due on the earlier of the three-year anniversary or upon sale of the counterparties. The Company had no cost basis
in the units and as a result the note receivable has no cost basis. The Company accounts for the note receivable as a loan pursuant to
ASC 310 – Loans . The $1 million in deferred payments was recorded with an implied discount of approximately $107,000, which is
to be amortized over 3 years. During the nine months ended September 30, 2022, the Company accepted an offer to settle note balance for
a one-time payment of $900,000. Notes receivable as of September 30, 2022 and December 31, 2021 amounted to $0 and $935,000, respectively.
NOTE
5 – MARKETABLE SECURITIES
The
Company offers its customers the option to settle the contract price in the customer’s issued and publicly trading securities or
securities convertible into publicly traded securities (e.g., convertible debt), which could be in the form of common stock, preferred
stock or convertible debentures. The Company initially values the securities received at the fair market value on the date the contract
is executed, which value is used for revenue recognition purposes. After receipt of the securities, the securities are accounted for
as investments in debt and equity securities. The Company has concluded that all its debt securities should be classified as trading
securities based on its intent to sell them in the near term. Debt securities classified as trading securities and the equity securities
are measured at each reporting period at fair value with changes reported in earnings. Upon the sale of the securities, the Company recognizes
the final realized gain or (loss) in the consolidated statement of operations as a component of net income (loss).
As
of September 30, 2022 marketable securities amounted to $21,121,000, with a current portion $2,918,000, and the long term portion of
$18,203,000.
The
following tables summarize the changes in the Company’s marketable securities during the nine months ended September 30, 2022:
SCHEDULE
OF MARKETABLE SECURITIES
| |
Total | | |
Common Stock | | |
Convertible Debentures | | |
Preferred Stock | | |
Warrants | |
Balance as of December 31, 2021 | |
$ | 15,617,000 | | |
$ | 10,735,000 | | |
$ | 4,187,000 | | |
$ | 599,000 | | |
$ | 96,000 | |
Transfers | |
| - | | |
| 356,000 | | |
| (325,000 | ) | |
| (31,000 | ) | |
| - | |
Additions | |
| 15,943,000 | | |
| 14,006,000 | | |
| 937,000 | | |
| 1,000,000 | | |
| - | |
Sales proceeds | |
| (3,385,000 | ) | |
| (3,385,000 | ) | |
| - | | |
| - | | |
| - | |
Realized loss | |
| (6,521,000 | ) | |
| (6,521,000 | ) | |
| - | | |
| - | | |
| - | |
Current period change in fair value | |
| (533,000 | ) | |
| (3,462,000 | ) | |
| 4,429,000 | | |
| (1,467,000 | ) | |
| (33,000 | ) |
Balance as of September 30, 2022 | |
$ | 21,121,000 | | |
$ | 11,729,000 | | |
$ | 9,228,000 | | |
$ | 101,000 | | |
$ | 63,000 | |
The
Company’s sales of securities for the nine months ended September 30, 2022, was approximately $3.4 million, with a book basis of
approximately $9.9 million which represented a loss of approximately $6.5 million, which the Company recorded as other expense included
in the gains from marketable securities.
The
equity securities may be accounted for and classified into two categories and accounted for as follows:
|
● |
Equity
securities with a readily determinable fair value are reported at fair value, with unrealized gains and losses included in earnings.
The fair value of equity investments with fair values is primarily obtained from third-party pricing services. |
|
|
|
|
● |
Equity
securities without a readily determinable fair value are reported at their cost minus impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or similar investment of the same issuer and their impact
on fair value. For equity investments without readily determinable fair values, when an orderly transaction for the identical or
similar investment of the same issuer is identified, the Company uses valuation techniques to evaluate the observed transaction(s)
and adjust the fair value of the equity investment. |
Concentration
Risk
The
Company’s holdings in marketable securities subject the Company to concentrations of market risks. As of September 30, 2022, the
Company’s top marketable security position had a fair value of $2.3 million, which represented approximately 11% of the Company’s
holdings, the top five marketable security positions had an aggregate fair value of $8.7 million, which represented approximately 41%
of the Company’s holdings, and the top ten marketable security positions had an aggregate fair value of $13.0 million, which represented
approximately 61% of the Company’s holdings
Volatility
The
Company’s holdings in marketable securities are subject to a high level of volatility, and can experience drastic price changes.
BIGtoken
Investment
On
February 15, 2022, the Company entered into a simple agreement for future equity (the “SAFE”) with its former BIGToken subsidiary.
Pursuant to the SAFE, the Company invested $1,000,000 in the SAFE. The amount funded into the SAFE at a given time is referred to herein
as the “SAFE Amount”. The Company is accounting for the SAFE as an equity investment carried at fair value with changes recorded
in earnings each period and is reflected as such in the above table. As of September 30, 2022 the SAFE had an aggregate fair value of
$0, as the Company believed the SAFE to have no value due to the financial condition its former BIGToken subsidiary.
Pursuant
to the terms of the SAFE, at any time that BIGtoken sells its securities (a “Financing”) prior to the termination of the
SAFE, the Company may, at its option, convert the SAFE into: (i) the number of shares of non-voting Series D Convertible Preferred Stock
(“Series D Preferred Stock”) equal to such (a) SAFE Amount divided by (b) the lowest price per share of equity securities
sold in any Financing (prior to the termination of the SAFE) multiplied by eighty percent (80%) (the “Conversion Price”)
and (ii) such number of warrants to purchase Series D Preferred Stock (the “Warrants”) equal to the SAFE Amount divided by
the Conversion Price. Upon issuance, the Warrants will (i) have a term of five (5) years, (ii) an exercise price equal to the Conversion
Price, and (iii) contain price protection provisions for subsequent financings.
NOTE
6 – DESIGNATED ASSETS FOR RETURN OF CAPITAL
On
August 17, 2021, the Company announced that it will be issuing a one-time dividend consisting of a share of Series A Preferred Stock
to shareholders, debenture holders, and certain warrant holders (“Recipients”) of record on September 20, 2021. The Board
of Directors designated certain of the Company’s marketable equity securities (“Designated Assets”) as of September
20, 2021 to be used when liquidated, as a return of capital to the Recipients. See Note 9 - Series A Preferred Stock for more details.
The
balance of designated assets consists of the following:
SCHEDULE
OF DESIGNATED ASSETS
| |
September 30, 2022 | | |
December 31, 2021 | |
Cash | |
$ | - | | |
$ | 686,000 | |
Marketable equity securities | |
| 221,000 | | |
| 3,239,000 | |
Total | |
$ | 221,000 | | |
$ | 3,925,000 | |
The
marketable equity security activity in designated assets is as follows:
SCHEDULE
OF MARKETABLE EQUITY SECURITY ACTIVITY IN DESIGNATED ASSETS
| |
Total | |
Balance as of December 31, 2021 | |
$ | 3,239,000 | |
Sales proceeds | |
| ) |
Realized loss | |
| (1,803,000 | ) |
Current period change in fair value | |
| (710,000 | ) |
Balance as of September 30, 2022 | |
$ | 221,000 | |
The
Company’s sale of marketable securities underlying designated assets for the nine months ended September 30, 2022, were approximately
$0.5 million with a cost basis of approximately $2.3 million, which resulted in a realized loss of approximately $1.8 million, which
the Company recorded as other expense included in the realized loss from designated assets.
NOTE
7 – SALES AND PURCHASE OF ACCOUNTS RECEIVABLE AND SHORT TERM FINANCINGS
Sales
of Accounts Receivable
In
2020, the Company entered into certain financing agreements providing for the sale, with full recourse, of certain of its accounts receivable.
These transactions were accounted for as financing of accounts receivables and the related accounts receivable were not removed from
the Company’s consolidated balance sheet at the time of the transaction; rather, a liability was recorded for the proceeds received.
In 2020 subsequent to the transactions, the purchaser converted the payables into approximately $788,000 of the OID Convertible Notes
payable (“Debentures”) (See Note 8 - OID Convertible notes payable).
For
the year ended December 31, 2021, the Company entered into agreements with a third-party lender whereby it sold the Company’s right
to future subscription revenues of $625,000 for net proceeds of $576,000. Under the terms of the agreement, the Company may borrow funds
collateralized by the right to the revenues from Sequire platform contracts. The third-party lender receives a discount on the amount
sold and remits the net amount to the Company. The Company bears the risk of credit loss on the contracts. These transactions are accounted
for as secured borrowing arrangements and not as a sale of financial assets. During the six months ended June 30, 2022 the Company entered
into agreements with third party lenders to borrow against future receipts in the amount of $4,170,000 for net proceeds of $3,044,000.
These borrowings have terms of less than 12 months.
In
August 2022, proceeds from the Senior Secured Revolving Credit Facility were used to pay off the entire balance of outstanding borrowings.
The amount of borrowings outstanding was approximately $0 and $633,000 as of September 30, 2022 and December 31, 2021, respectively,
and are included in other current liabilities within our unaudited condensed consolidated balance sheets.
CVR
Agreement
During
the nine months ended September 30, 2022, the Company entered into an agreement with an institutional investor whereby in exchange for
the payment of $405,000, the investor received (i) the right to receive the net proceeds upon the sale of certain marketable securities
held by the Company with a guaranteed minimum return of 120% of such Purchase Price or $486,000 and (ii) the right after 90 days but
before 120 days to demand payment of 120% of the Purchase Price in cash less amounts previously paid from the sales of such securities.
As of September 30, 2022 a liability in the amount of $613,000 was recorded in other current liabilities within our unaudited condensed
consolidated balance sheets.
NOTE
8 – OID CONVERTIBLE NOTE(S) PAYABLE
On
June 30, 2020, the Company entered into a definitive securities purchase agreement (the “Securities Purchase Agreement or Transaction”)
with certain accredited and institutional investors (the “Purchasers”) for the purchase and sale of an aggregate of: (i)
$16,101,000 in principal amount of Original Issue Discount Senior Secured Convertible Debenture (the “Debentures”) for $14,169,000
(representing a 12% original issue discount) (“Purchase Price”) and (ii) warrants to purchase up to 6,440,561 shares of the
Company’s Class A common stock (the “Warrants”) in a private placement (the “Offering”). The Purchase Price
consisted of (a) $13,000,000 in cash and (b) the cancellation of $1,169,000 in outstanding debt. The Company received net proceeds of
approximately $9,100,000 after deducting the Placement Agent fees, the Debt Repayments and other offering expenses. The Company’s
obligations under the Debentures are secured by substantially all of the assets of the Company.
The
Debentures pay interest in cash at the rate of 12.0% per annum commencing on June 30, 2021, with such interest originally payable quarterly,
beginning on October 1, 2021. Commencing after the six-month anniversary of the issuance of the Debentures, the Company was required
to make amortization payments (“Amortization Payments”) with each Purchaser having the right to delay such Amortization Payments
by a six-month period up to three separate times (each, an “Extension”) in exchange for five percent (5%) in principal being
added to the balance of such applicable Debenture on each such Extension. The Debentures had an original maturity date of December 31,
2021 but were extended three times and now mature on June 30, 2023. Beginning on the date that the first Amortization Payment is due,
and on a monthly basis thereafter, the Company will be required to pay one hundred fifteen percent of the value of one-twelfth of the
outstanding principal plus any additional accrued interest due.
The
Debentures are convertible at the option of the holder into shares of the Company’s common stock at an initial conversion price
of $2.69 per share, subject to adjustment in the event of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata
distributions, and (iv) certain fundamental transactions, including but not limited to the sale of the Company, business combinations,
and reorganizations.
In
the event a Purchaser converts a portion of its Debenture into shares of the Company’s Common Stock, such amount will be deducted
from the next applicable Amortization Payment. In the event such conversion exceeds the next applicable Amortization Payment, such excess
amount will be deducted, in reverse order, from future Amortization Payments.
Pursuant
to the terms of the Debentures and Warrants, a Purchaser will not have the right to convert any portion of the Debentures or exercise
any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% (at the Purchaser’s
option) of the number of shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as such percentage
ownership is determined in accordance with the terms of the Debentures and the Warrants; provided that at the election of a holder and
notice to us such percentage ownership limitation may be increased to 9.99%; provided that any increase will not be effective until the
61st day after such notice is delivered from the holder to the Company.
Subject
to the Company’s compliance with certain conditions, upon ten trading days’ notice to the Purchasers, the Company has the
right to redeem the Debentures in cash at 115% of their outstanding principal, plus accrued interest. Additionally, in the event that
the Company (i) sells or reprices any securities (each, a “Redemption Financing”), or (ii) disposes of assets (except those
sold or transferred in the ordinary course of business) (each, an “Asset Sale”), then the Purchasers shall have the right
to (a) in the event of a Redemption Financing at a price per Common Stock equivalent of $2.50 or less per share, the Purchasers may mandate
that 100% of the proceeds be used to redeem the Debentures (b) in the event of a Redemption Financing at a price per Common Stock equivalent
of greater than $2.50 per share, the Purchasers may mandate that up to 50% of the proceeds be used to redeem the Debentures, and (c)
in the event of an Asset Sale, the Purchasers may mandate that up to 100% of the proceeds be used to redeem the Debentures.
The
Debentures also contain certain customary events of default provisions, including, but not limited to, payment default, breaches of covenants,
the occurrence of an event of default under certain material contracts of the Company, failure to register the shares underlying the
Debentures and Warrants, changes in control of the Company, delisting of its securities from its trading market, and the entering or
filing of certain monetary judgments against the Company. Upon the occurrence of any such event of default, the outstanding principal
amount of the Debenture plus liquidated damages, interest and other amounts owing in respect thereof through the date of acceleration,
shall become, at the Purchaser’s election, immediately due and payable in cash. The Company is also prohibited from certain activities
(unless waived by 67% of the then outstanding Purchasers, and including the lead Purchaser), including but not limited to, the creation
of certain debt obligations, liens on Company assets, amending its charter documents, repayment or repurchase of securities or certain
debt of the Company, or the payment of dividends.
The
Warrants are initially exercisable at $2.50 per share and, are subject to cashless exercise after six months if the shares underlying
the Warrants are not subject to an effective resale registration statement. The Warrants are also subject to adjustment in the event
of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata distributions, and (iv) certain fundamental transactions,
including but not limited to the sale of the Company, business combinations, and reorganizations.
Pursuant
to a registration rights agreement (“Registration Rights Agreement”), the Company has agreed to file a registration statement
registering the resale of the shares of the common stock underlying the Debentures and the Warrants within forty-five days from the date
of the Registration Rights Agreement. The Company also agrees to have the registration statement declared effective within 90 days from
the date of the Registration Rights Agreement and keep the registration statement continuously effective until the earlier of (i) the
date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be
registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule
144 under the Securities Act. The Company is also obligated to pay the Investors, as partial liquidated damages, a fee of 2.0% of each
Purchaser’s subscription amount per month in cash upon the occurrence of certain events, including the Company’s failure
to file and/or have the registration statement declared effective within the time periods provided. As of June 30, 2022, the Company
has continuously met its obligations under the Registration Rights Agreement.
Bradley
Woods & Co. Ltd. (“Placement Agent”) acted as the placement agent, in connection with the sale of the securities. Pursuant
to an engagement agreement, the Company agreed to pay the Placement Agent a cash commission of $1,040,000 and issue an aggregate of 478,854
Common Stock purchase warrants (“PA Warrants”). The PA Warrants are substantially similar to the Warrants, except that the
PA Warrants have an exercise price of $3.3625 per share. Additionally, upon the exercise of the Warrants issued in the Offering, the
Placement Agent will be entitled to eight percent (8%) of the cash proceeds received from such exercises. The fair value of the PA Warrants
at issuance was estimated to be $360,000.
The
Company first allocated the cash proceeds to the loan and the equity classified warrants on a relative fair value basis, secondly, the
proceeds were allocated to the beneficial conversion feature. The proceeds allocated to the warrants and the beneficial conversion feature
resulted in a debt discount being amortized as additional interest expense using the effective interest method over the term.
Extension
of Outstanding Original Issue Discount Senior Secured Convertible Debentures
On
July 1, 2022, the holders (“Holders”) of $1,197,000 in principal of the Company’s Original Issue Discount Senior Secured
Convertible Debentures (“Debentures”), representing all of the outstanding Debentures that were originally issued on June
30, 2020, entered into an agreement with the Company to (i) extend the maturity date of the Debentures until June 30, 2023 and (ii) extend
the first date that monthly redemptions are required to be made by the Company to begin on January 1, 2023 (the “Debenture Extension”).
As consideration for the Debenture Extension, the Company increased the principal amount outstanding on the Debentures by five percent
(5%). Additionally, the holders of the Debentures have the unilateral right to extend the maturity date and monthly redemption period
by an additional six (6) month period at any time prior to January 1, 2023 for an additional five percent (5%) to be added to the outstanding
principal of such Debentures. The Debentures, including the additional principal added to the Debentures are secured by substantially
all of the assets of the Company pursuant to a security agreement entered into between the Company and Holders contemporaneous with the
original issuance of the Debentures (the “Security Agreement”). ATW Master Fund held the nearly all of the $1,197,000 in
Debenture principal on June 30, 2020.
Amendment
of Convertible Debenture
On
September 13, 2023, the remaining Debenture, solely held by ATW Master Fund was temporarily amended for a period of up to fourteen months
from the Effective date of September 11, 2023. The amendments include, but are not limited to, provisions related to the payment of amounts
owing under the Credit Agreement from the proceeds of the sale of third-party securities held by the company. Per the agreement ATW shall
receive one hundred percent of the proceeds from sales from third party securities owned by the Company until such time as outstanding
amounts due under the respective agreements have been repaid. The Company shall maintain the rights to all proceeds from sales of the
marketable securities once the amounts due to ATW have been satisfied. The Company also agreed to various covenants and conditions, including
providing access to certain accounts and notifying ATW Opportunities and ATW Master Fund of material changes.
The
table below summarizes the Debenture related activity during the three and nine months ended September 30, 2022:
SCHEDULE
OF OID CONVERTIBLE DEBENTURES
| |
Principal | | |
Debt Discount | | |
Net Book Value | |
Balance as of December 31, 2021 | |
$ | 1,267,000 | | |
$ | (103,000 | ) | |
$ | 1,164,000 | |
Amortization | |
| - | | |
| 17,000 | | |
| 17,000 | |
Balance as of March 31, 2022 | |
$ | 1,267,000 | | |
$ | (86,000 | ) | |
$ | 1,181,000 | |
Amortization | |
| - | | |
| 16,000 | | |
| 16,000 | |
Balance as of June 30, 2022 | |
$ | 1,267,000 | | |
$ | (70,000 | ) | |
$ | 1,197,000 | |
Principal adjustments | |
| 74,000 | | |
| - | | |
| 74,000 | |
Repayments | |
| (195,000 | ) | |
| - | | |
| (195,000 | ) |
Amortization | |
| - | | |
| 18,000 | | |
| 18,000 | |
Balance as of September 30, 2022 | |
$ | 1,146,000 | | |
$ | (52,000 | ) | |
$ | 1,094,000 | |
NOTE
9 – SENIOR SECURED REVOLVING CREDIT FACILITY (REVOLVING NOTE)
Bridge
Note
On
July 1, 2022, the Company issued an original issue discount bridge note in principal amount of $650,000 (“Bridge Note”) to
an institutional investor in exchange for $500,000 in cash. The bridge note was non-interest bearing and had a maturity date of August
15, 2022. The Company’s obligations pursuant to the bridge note were secured by substantially all of the assets of the Company
pursuant to the terms of the Security Agreement.
On
August 8, 2022, as described below, the Bridge Note was exchanged for a revolving note in the Senior Secured Revolving Credit Facility.
Senior
Secured Revolving Credit Facility (Revolving Note)
On
August 8, 2022, the Company entered into a senior secured revolving credit facility agreement with ATW Opportunities fund to initially
borrow up to $9,450,000 in the aggregate from time to time (each a “Revolving Note”). The loan maximum amount accessible
is limited to $5.5 million until the Company is current with its reporting obligations. The loan is secured by all the assets of the
Company and is guaranteed by the Company’s wholly owned subsidiary, LD Micro, Inc. As part of the transaction, the Company also
amended and restated lender’s outstanding warrants to extend the maturity date of a total of 2,590,358 Common Stock purchase warrants
until September 30, 2023.
On
closing, the lender advanced $5,580,000 consisting of $4,930,000 in cash and the exchange of the existing outstanding $650,000 bridge
note. Upon the Company meeting certain conditions, the Lender will advance up to an additional $3,870,000.
The
principal balance of each Revolving Note will reflect an original issue discount of ten percent (10%); provided that beginning on the
date that is twelve (12) months from the Effective Date, such original issue discount will increase to twelve percent (12%) in the event
the Prime borrowing rate increases to 6.75%, and 18% in the event of default. The Revolving Note have a maturity date of the earlier
of (i) twenty-four (24) months from the Effective Date or (ii) the occurrence of an event of default, as described in the Loan Documents.
Commencing
on the first day of each month after the Effective Date, the outstanding balance of the Revolving Note will be paid as calculated based
on a percentage of the Company’s collections from the sale of certain of its marketable securities.
The
Revolving Note is initially convertible into shares of Common Stock at a conversion price of $15.00 per share (“Conversion Price”).
The Conversion Price is subject to adjustment in the event of stock splits, dividends, fundamental transactions and certain future sales
of the Company’s Common Stock.
As
consideration for Lender entering into the Loan Documents, Lender will be entitled to receive, in addition to any payment made under
the Credit Agreement, 10% of the net proceeds received by the Company from the sales of securities received during the term of the Revolving
Note.
For
the Company to enter into the Credit Agreement, we were required to issue 33,000 shares of the Company’s common stock as a breakup
fee to an unrelated lender as a result of a failed offering.
Amendment
of Senior Secured Revolving Credit Facility
On
September 13, 2023, the Revolving Note and Credit Agreement were temporarily amended for a period of up to fourteen months from the Effective
date of September 11, 2023. The amendments include, but are not limited to, provisions related to the payment of amounts owing under
the Credit Agreement from the proceeds of the sale of third-party securities held by the company. Per the agreement ATW shall receive
one hundred percent of the proceeds from sales from third party securities owned by the Company until such time as outstanding amounts
due under the respective agreements have been repaid. The Company shall maintain the rights to all proceeds from sales of the marketable
securities once the amounts due to ATW have been satisfied.
The
Company also agreed to various covenants and conditions, including providing access to certain accounts and notifying ATW Opportunities
and ATW Master Fund of material changes.
The
table below summarizes the senior secured revolving credit facility related activity during the three months ended September 30, 2022:
SCHEDULE
OF SENIOR SECURED REVOLVING CREDIT FACILITY RELATED ACTIVITY
| |
Principal | | |
Debt Discount | | |
Net Book Value | |
Balance as of June 30, 2022 | |
$ | - | | |
$ | - | | |
$ | - | |
Loan proceeds | |
| 6,128,000 | | |
| - | | |
| 6,128,000 | |
Original issue discount | |
| - | | |
| (750,000 | ) | |
| (750,000 | ) |
Repayments | |
| (4,000 | ) | |
| - | | |
| (4,000 | ) |
Amortization | |
| - | | |
| 104,000 | | |
| 104,000 | |
Balance as of September 30, 2022 | |
$ | 6,124,000 | | |
$ | (646,000 | ) | |
$ | 5,478,000 | |
Extension
of Warrants
As
part of the transactions contemplated by the Revolving Note, the Company additionally agreed to extend the expiration dates of the following
outstanding Common Stock purchase warrants held by the Lender or its affiliated entities until September 30, 2023:
(a)
a warrant to purchase 1,313,636 shares of Common Stock issued on June 30, 2020, that was initially disclosed on the Company’s Current
Report on Form 8-K filed with the SEC on June 30, 2020;
(b)
a warrant to purchase 166,667 shares of Common Stock issued on November 29, 2018, that was initially disclosed on the Company’s
Current Report on Form 8-K filed with the SEC on November 30, 2018; and
(c)
a warrant to purchase 480,027 shares of Common Stock issued on November 29, 2018, that was initially disclosed on the Company’s
Current Report on Form 8-K filed with the SEC on November 30, 2018;
(d)
a warrant to purchase 480,028 shares of Common Stock issued on October 27, 2017 that was initially disclosed on the Company’s Current
Report on Form 8-K filed with the SEC on October 27, 2017.
NOTE
10 – COMMON AND PREFERRED STOCK
Common
Stock
The
Company’s certificate of incorporation provides for two classes of common stock: Class A common stock (authorized 250,000,000 shares,
par value $0.001), which has one vote per share, and Class B common stock (authorized 9,000,000 shares, par value $0.001), which has
ten votes per share. Any holder of Class B common stock may convert his or her shares at any time into shares of Class A common stock
on a share-for-share basis. Otherwise, the rights of the two classes of common stock are identical.
In
August 2021, the Board of Directors approved a share repurchase program pursuant to which the Company is authorized to repurchase up
to $10,000,000 of Class A Common Stock in privately negotiated transactions or in the open market at prices per share not exceeding the
then-current market prices. Under the program, management has discretion to determine the dollar amount of shares to be repurchased and
the timing of any repurchases in compliance with applicable law and regulation. This includes purchases pursuant to Rule 10b5-1 plans,
including accelerated share repurchases. The program does not have an expiration date.
During
the year ended December 31, 2021, the Company repurchased 155,000 shares of Common Stock, for an aggregate purchase price of $793,000
pursuant to the Company’s Share Buy-Back program. The shares were retired as of December 31, 2021. No amounts were repurchased
in the six months ended June 30, 2022. The total remaining authorization for future common share repurchases under the Company’s
share repurchase program was $9.2 million as of June 30, 2022.
During
the year ended December 31, 2021, the Company sold 53,616 shares of common stock, resulting in proceeds of approximately $284,000, through
sales under its At the Market (ATM) offering.
On
January 2, 2022, Michael Malone, our former Chief Financial Officer exercised an option to purchase 100,000
shares of our common stock that was issued on December 15, 2018. The option was exercised on a cashless basis and included 57,016
shares withheld pursuant to the cashless exercise and an additional 16,732
shares withheld for tax withholding. Accordingly, we issued Mr. Malone 26,252
shares of common stock.
During
the month of January 2022, non-executive employees exercised a total of 227,667 stock options. These options were exercised on a cashless
basis, and included 161,938 shares withheld pursuant to cashless exercise and tax withholdings. This resulted in the issuance of 65,729
shares of common stock.
During
the month of July 2022, the Company issued 31,872 shares of common stock from the exercise of 100,000 stock options on a cashless basis
by an executive.
During
the three months ended June 30, 2022, the Company issued 203,926 shares of common stock from the exercise of 697,574 warrants, including
689,173 that were exercised on a cashless basis, and 8,401 exercised for $32,000 in cash.
Preferred
Stock
The
Company is authorized to issue 50,000,000 of preferred stock, par value $0.001, of which 36,462,417 shares are designated as Series A
Preferred Stock (“Dividend Shares”). The Company’s Board of Directors, without further stockholder approval, may issue
preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences,
qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different
series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights,
redemption provisions, sinking fund provisions and other matters. The Board of Directors may authorize the issuance of preferred stock,
which ranks senior to the Company’s common stock for the payment of dividends and the distribution of assets on liquidation. In
addition, the Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of the Company’s
common stock to be effective while any shares of preferred stock are outstanding.
On
September 20, 2021, the Company filed a certificate of designation (the “COD”) of preferences, rights, and limitations of
Series A Non-Voting Preferred Stock (“Series A Preferred Stock”) with the Secretary of State of Delaware. Pursuant to the
COD, the Company is authorized to issue up to 36,462,417 shares of Series A Preferred Stock (the “Dividend Shares”).
On
September 27, 2021, the Company issued a one-time dividend of 36,462,417 shares of series A preferred stock (“Preferred Stock”)
to certain Qualified Recipients (the “Dividend”). The preferred stock entitles the Qualified Recipients with the right to
receive the net proceeds from sales of certain marketable securities that the Company received through its Sequire Platform services.
See Note 6 – Designated Assets for Return of Capital.
As
of the Record Date, the following holders of securities were entitled to receive the Dividend (collectively, the “Qualified Recipients):
|
i. |
each
outstanding share of Class A common stock (the “Common Stock”), of which 25,160,504 shares were issued and outstanding, |
|
|
|
|
ii. |
each
share of Common Stock underlying outstanding common stock purchase warrants containing a contractual right to receive the Dividend
(“Warrants”) of which, 10,327,645 were outstanding, and |
|
|
|
|
iii. |
each
original issue discount senior convertible debenture (the “Debentures”) issued on June 30, 2021, containing a contractual
right to receive the Dividend on an as converted to Common Stock basis, of which $2,486,275 of Debentures were outstanding in principal
and interest, convertible into 974,268 shares of Common Stock. |
The
Company’s management has evaluated the Preferred Stock and determined that Preferred Stock is mandatorily redeemable upon the distribution
of the net proceeds from the sale of the designated marketable securities. Accordingly, it is classified as a liability recorded at fair
value, with changes in fair value being reflected in earnings.
Preferred
stock liability represents amounts payable to holders of the Preferred Stock Series A shares upon the eventual liquidation of assets
designated for the sole purpose of paying dividends. Accordingly, the Company classified the Series A Preferred Shares as liability instruments
because in-substance, they represent a right to the payment of dividends upon the liquidation of specified assets, are automatically
returnable to the Company after the payments are made and feature no rights to further equity or residual interests in the Company. The
Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Preferred Stock states dividend shall be paid
conditioned upon, and subject to a determination by the Board that a distribution is not prohibited pursuant to applicable provisions
of the DGCL or other applicable law.
NOTE
11 – EQUITY COMPENSATION PLANS AND WARRANTS
Equity
Compensation Plans
As
of September 30, 2022, the Company has approximately 228,000 shares of Class A Common Stock reserved for issuance under the Company’s
equity compensation plans.
For
the nine months ended September 30, 2022, the Company issued the below shares and granted the following stock-based awards:
On
January 2, 2022, Michael Malone, our former Chief Financial Officer exercised an option to purchase 100,000
shares of our common stock that was issued on December 15, 2018. The option was exercised on a cashless basis and included 57,016
shares withheld pursuant to the cashless exercise and an additional 16,732
shares withheld for tax withholding. Accordingly, we issued Mr. Malone 26,252
shares of common stock.
On
January 3, 2022, we issued four (4) common stock purchase options to our non-employee directors, pursuant to our amended non-employee
director compensation policy. Each option entitled the holder to purchase 29,533 shares of common stock at an exercise price of $4.35
per share, for an aggregate exercise amount of $128,500. The options vest in equal quarterly over a one (1) year period from the issuance
date. The options expire on the seven (7) year anniversary of the issuance date. Each option has a Black-Scholes value of $100,000.
During
the month of January 2022, non-executive employees exercised a total of 227,667 stock options. These options were exercised on a cashless
basis, and included 161,938 shares withheld pursuant to cashless exercise and tax withholdings. This resulted in the issuance of 65,729
shares of common stock.
On
January 6, 2022, we issued non-executive employees, options to purchase 380,000 shares of Class A common stock. The option has an exercise
price of $4.25 per share, a term of five (5) years and vests in equal quarterly installments over a three (3) year period from the grant
date. The option had a Black-Scholes value on the grant date of $1,038,000.
On
January 6, 2022, we issued Christopher Miglino, our Chief Executive Officer, an option to purchase 120,000 shares of common stock. The
option has an exercise price of $4.25 per share, a term of seven (7) years and vests in equal quarterly installments over a three (3)
year period from the grant date. The option had a Black-Scholes value on the grant date of $356,000.
On
January 6, 2022, we issued an employee an option to purchase 100,000 shares of common stock. The option has an exercise price of $4.25
per share, a term of seven (7) years and vests in equal quarterly installments over a three (3) year period from the grant date. The
option had a Black-Scholes value on the grant date of $296,000.
On
January 6, 2022, we issued Michael Malone, our former Chief Financial Officer, a conditional option to purchase 100,000
shares of Class A common stock. The option is a conditional grant, subject to shareholder approval. Assuming approval by the
shareholders, the option has an exercise price of $4.25
per share, a term of seven (7)
years and vests in equal quarterly installments over a three (